A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with advanced solid malignancies Academic Article uri icon

Overview

MeSH Major

  • Adenosylmethionine Decarboxylase
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Neoplasms
  • Polyamines

abstract

  • SAM486A was well tolerated on this schedule of administration with the MTD established at 102.4 mg/m(2)/day. Neutropenia was dose-limiting and correlated with dose and area under the concentration-time curve. Pharmacodynamic assessment of tumoral tissues in 1 study patient demonstrated changes in the levels of polyamines and their biosynthetic enzymes consistent with SAMDC inhibition.

publication date

  • January 2002

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 12114416

Additional Document Info

start page

  • 2157

end page

  • 66

volume

  • 8

number

  • 7